CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.24 and traded as low as $0.23. CytoDyn shares last traded at $0.24, with a volume of 1,440,438 shares trading hands.
CytoDyn Stock Performance
The stock has a market capitalization of $287.28 million, a P/E ratio of -23.31 and a beta of -0.28. The firm has a fifty day moving average price of $0.24 and a two-hundred day moving average price of $0.17.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Further Reading
- Five stocks we like better than CytoDyn
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 03/24 – 03/28
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Ride Out The Recession With These Dividend Kings
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
